SEARCH

SEARCH BY CITATION

References

  • 1
    Duarte C.D., Barreiro E.J., Fraga C.A.M. (2007) Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini-Rev Med Chem;7:11081119.
  • 2
    Essman W.B. (1973) Subcellular actions of benzodiazepines. In: GarattiniS., MussiniE., RandallL.O., editors. The Benzodiazepines. New York: Raven Press; p. 177190.
  • 3
    Horton D.A., Bourne G.T., Smythe M.L. (2003) The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem Rev;103:893930.
  • 4
    Kamal A., Reddy K.L., Devaiah V., Shankaraiah N., Reddy D.R. (2006) Recent advances in the solid-phase combinatorial synthetic strategies for the benzodiazepine based privileged structures. Mini-Rev Med Chem;6:5369.
  • 5
    Reid T.S., Beese L.S. (2004) Crystal structures of the anticancer clinical candidates R1 15777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity. Biochemistry;43:68776884.
  • 6
    Leonard K., Marugan J.J., Raboisson P., Calvo R., Gushue J.M., Koblish H.K., Lattanze J., Zhao S.Y., Cummings M.D., Player M.R., Maroney A.C., Lu T.B. (2006) Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity. Bioorg Med Chem Lett;16:34633468.
  • 7
    Verdie P., Subra G., Averland-Petit M.-C., Amblard M., Martinez J. (2008) Solid-phase synthesis of 4-methylcarboxy-1,4-benzodiazepine-2,5-diones. J Comb Chem;10:869874.
  • 8
    Saudo M., Garcia-Valverde M., Marcaccini S., Delgado J.J., Rojo J., Torroba T. (2009) Synthesis of benzodiazepine beta-turn mimetics by an Ugi 4CC/Staudinger/aza-Wittig sequence. Solving the conformational behavior of the Ugi 4CC adducts. J Org Chem;74:21892192.
  • 9
    Rosenstrom U., Skold C., Lindeberg G., Botros M., Nyberg F., Karlen A., Hallberg A. (2006) Design, synthesis, and incorporation of a beta-turn mimetic in angiotensin II forming novel pseudopeptides with affinity for AT1 and AT2 receptors. J Med Chem;49:61336137.
  • 10
    McDowell R.S., Blackburn B.K., Gadek T.R., McGee L.R., Rawson T., Reynolds M.E., Robarge K.D., Somers T.C., Thorsett E.D., Tischler M., Webb R.R., Venuti M.C. (2002) From peptide to non-peptide. 2. The de novo design of potent, non-peptidal inhibitors of platelet aggregation based on a benzodiazepinedione scaffold. J Am Chem Soc;116:50775083.
  • 11
    Loudni L., Roche J., Potiron V., Clarhaut J., Bachmann C., Gesson J.-P., Tranoy-Opalinski I. (2007) Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors. Bioorg Med Chem Lett;17:48194823.
  • 12
    Carlier P.R., Zhao H., MacQuarrie-Hunter S.L., DeGuzman J.C., Hsu D.C. (2006) Enantioselective synthesis of diversely substituted quaternary 1,4-benzodiazepin-2-ones and 1,4-benzodiazepine-2,5-diones. J Am Chem Soc;128:1521515220.
  • 13
    Goff D.A., Zuckermann R.N. (1995) Solid-phase synthesis of defined 1,4-benzodiazepine-2,5-dione mixtures. J Org Chem;60:57445745.
  • 14
    Alig L., Chucholowski A., Weller T. (2001) Benzazepinone and quinazoline derivatives inhibiting the binding of adhesive proteins to vitronectin receptors. WO2001004103.
  • 15
    Parks D.J., LaFrance L.V., Calvo R.R., Milkiewicz K.L., Marugan J.J., Raboisson P., Schubert C., et al. (2006) Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. Bioorg Med Chem Lett;16:33103314.
  • 16
    Verdie P., Subra G., Feliu L., Sanchez P., Berge G., Garcin G., Martinez J., et al. (2007) On-line synthesis of pseudopeptide library incorporating a benzodiazepinone turn mimic: biological evaluation on MC1 receptors. J Comb Chem;9:254262.
  • 17
    Chen X., Chen X., Connors R.V., Dai K., Fu Y., Jaen J.C., Kim Y.-J., Li L., Lizarzaburu M.E., Mihalic J.T., Shuttleworth S.J. (2006) Preparation of benzo-fused heterocycles for treatment of obesity and eating disorders. WO2006020959.
  • 18
    Costantino L., Barlocco D. (2006) Privileged structures as leads in medicinal chemistry. Curr Med Chem;13:6585.
  • 19
    DeSimone R.W., Currie K.S., Mitchell S.A., Darrow J.W., Pippin D.A. (2004) Privileged structures: applications in drug discovery. Comb Chem High Throughput Screen;7:473493.
  • 20
    Burger A. (1991) Isosterism and bioisosterism in drug design. Prog Drug Res;37:287371.
  • 21
    Anderson D.R., Meyers M.J., Kurumbail R.G., Caspers N., Poda G.I., Long S.A., Pierce B.S., Mahoney M.W., Mourey R.J. (2009) Benzothiophene inhibitors of MK2. Part 1: structure-activity relationships, assessments of selectivity and cellular potency. Bioorg Med Chem Lett;19:48784881.
  • 22
    Zhu J., Bienaymé H., editors. (2005) Multicomponent Reactions. Weinheim: Wiley-VCH.
  • 23
    Dömling A. (2006) Recent developments in isocyanide based multicomponent reactions in applied chemistry. Chem Rev;106:1789.
  • 24
    Sabnis R.W., Rangnekar D.W., Sonawane N.D. (1999) 2-Aminothiophenes by the Gewald reaction. J Heterocycl Chem;36:333345.
  • 25
    Wang K., Kim D., Dömling A. (2010) Cyanoacetamide MCR (III): three-component Gewald reactions revisited. J Comb Chem;12:111118.
  • 26
    Huang Y., Dömling A. (2010) The Gewald multicomponent reaction. Mol Divers;14:DOI: 10.1007/s11030-010-9229-6 in press.
  • 27
    Dömling A., Ugi I. (2000) Multicomponent reactions with isocyanides. Angew Chem Int Ed;39:31693210.
  • 28
    Keating T.A., Armstrong R.W. (1996) A remarkable two-Step synthesis of diverse 1,4-benzodiazepine-2,5-diones using the Ugi four-component condensation. J Org Chem;61:89358939.
  • 29
    Hulme C., Ma L., Kumar N.V., Krolikowski P.H., Allen A.C., Labaudiniere R. (2000) Novel applications of resin bound alpha-amino acids for the synthesis of benzodiazepines (via Wang resin) and ketopiperazines (via hydroxymethyl resin). Tetrahedron Lett;41:15091514.
  • 30
    Faggi C., Marcaccini S., Pepino R., Pozo M.C. (2002) Studies on isocyanides and related compounds; Synthesis of 1,4-benzodiazepine-2,5-diones via Ugi four-component condensation. Synthesis;18:27562760.
  • 31
    Liu A., Zhou H., Su G., Zhang W., Yan B. (2009) Microwave-assisted fluorous synthesis of a 1,4-benzodiazepine-2,5-dione library. J Comb Chem;11:10831093.
  • 32
    Huang Y., Wolf S., Bista M., Meireles L., Holak T.A., Camacho C., Dömling A. (2010) 1,4-Thienodiazepine-2,5-diones via MCR (I): synthesis, virtual space and p53-Mdm2 activity. Chem Biol Drug Des;doi: 10.1111/j.1747-0285.2010.00989.x.
  • 33
    Wang W., Joyner S., Khoury K., Dömling A. (2010) (-)-Bacillamide C: the convergent approach. Org Biomol Chem;8:529532.
  • 34
    Jadidi K., Aryan R., Mehrdad M., Lugger T., Hahn F.E., Ng S.W. (2004) Simple synthesis, structure and ab initio study of 1,4-benzodiazepine-2,5-diones. J Mol Struct;692:3742.
  • 35
    Araujo A.C., Nicotra F., Airoldi C., Costa B., Giagnoni G., Fumagalli P., Cipolla L. (2008) Synthesis and biological evaluation of novel rigid 1,4-benzodiazepine-2,5-dione chimeric scaffolds. Eur J Org Chem;4:635639.
  • 36
    Antuch W., Menon S., Chen Q.-Z., Lu Y., Sakamuri S., Beck B. et al. (2006) Design and modular parallel synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhibitor scaffold. Bioorg Med Chem Lett;16:17401743.
  • 37
    Souers A.J., Ellman J.A. (2001) Beta-turn mimetic library synthesis: Scaffolds and applications. Tetrahedron;57:74317448.
  • 38
    Rose G.D., Gierasch L.M., Smith J.A. (1985) Turns in peptides and proteins. Adv Protein Chem;37:1109.
  • 39
    Oprea T.I. (2002) Chemical space navigation in lead discovery. Curr Opin Chem Biol;6:384389.
  • 40
    Oprea T.I. (2000) Property distribution of drug-related chemical databases. J Comput Aided Mol Des;14:251264.
  • 41
    Schneider G., Schneider P., Renner S. (2006) Scaffold-hopping: how far can you jump? QSAR Comb Sci;25:11621171.
  • 42
    Keating T.A., Armstrong R.W. (1996) Postcondensation modifications of Ugi four-component condensation products: 1-isocyanocyclohexene as a convertible isocyanide. Mechanism of conversion, synthesis of diverse structures, and demonstration of resin capture. J Am Chem Soc;118:25742583.
  • 43
    Hulme C., Peng J., Tang S.-Y., Burns C.J., Morize I., Labaudiniere R. (1998) Improved procedure for the solution phase preparation of 1,4-benzodiazepine-2,5-dione libraries via Armstrong’s convertible isonitrile and the Ugi reaction. J Org Chem;63:80218023.
  • 44
    Tempest P., Ma V., Kelly M.G., Jones W., Hulme C. (2001) MCC/SNAr methodology. Part 1: novel access to a range of heterocyclic cores. Tetrahedron Lett;42:49634968.
  • 45
    Marcaccini S., Miliciani M., Pepino R. (2005) A facile synthesis of 1,4-benzodiazepine derivatives via Ugi four-component condensation. Tetrahedron Lett;46:711713.
  • 46
    Cuny G., Bois-Choussy M., Zhu J. (2004) Palladium- and copper-catalyzed synthesis of medium- and large-sized ring-fused dihydroazaphenanthrenes and 1,4-benzodiazepine-2,5-diones. Control of reaction pathway by metal-switching. J Am Chem Soc;126:1447514484.